Last Published 01.01.2026 Effective Date: 01.01.2026 This policy addresses the use of Gamifant (emapalumab-lzsg) for the treatment of primary and secondary hemophagocytic lymphohistiocytosis (HLH)
The FDA has approved these agents based on extensive clinical trial data, but post-marketing surveillance continues to refine our understanding of their safety profile, including gastrointestinal and hepatobiliary effects
Saxenda and Wegovy are the drugs officially approved for weight management
At 5mg/ml : each unit contains 0.05mg (50mcg) of tirzepatide
L., Sitruk-Ware, R., Long, J., Bai, F., Hull, L., Bremner, W
Individual results vary depending on dose, adherence, diet, and physical activity